AVANIR Pharmaceuticals (AVNR)

16.96
0.00 (0.00)
NASDAQ : Health Care
Prev Close 16.96
Open 16.96
Day Low/High 16.96 / 16.98
52 Wk Low/High 3.02 / 17.05
Volume 8.44M
Avg Volume 6.29M
Exchange NASDAQ
Shares Outstanding 193.76M
Market Cap 3.29B
EPS -0.31
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Two Small-Cap Biotechs To Consider

Fibrocell Science and Prothena have several 'shots on goal.'

Next Year's Stock Returns: 5% or 15%?

Returns could be within this range in 2015.

Updating a Small Speculative Play

Synergy Pharmaceuticals is developing drugs to treat gastrointestinal disorders and diseases. The

Three Large-Cap Growth Stocks

I would pick up some large caps on any significant dips.

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Avanir Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Avanir Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...

Jim Cramer on the Stock Market: You Have to Love Biotech

Jim Cramer on the Stock Market: You Have to Love Biotech

In this era of turmoil, investors can take comfort in this sector.

Energy Stocks Shake Off Plunging Oil Prices to Push the Dow to New Highs

Energy Stocks Shake Off Plunging Oil Prices to Push the Dow to New Highs

Oil prices backtrack from Monday's bounce, but energy stocks shake it off. Instead, the sector gains more than 1% after several weeks of punishing losses.

Stocks Hover Near Highs as Oil Backtracks From Monday Bounce

Stocks Hover Near Highs as Oil Backtracks From Monday Bounce

Oil is back in the spotlight Tuesday as prices backtrack from Monday's bounce and move lower again.

AVANIR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Otsuka Pharmaceutical Co., Ltd.

AVANIR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Otsuka Pharmaceutical Co., Ltd.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Avanir...

EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Avanir Pharmaceuticals Concerning Its Proposed Sale To Otsuka Pharmaceutical - AVNR

EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Avanir Pharmaceuticals Concerning Its Proposed Sale To Otsuka Pharmaceutical - AVNR

The Rosen Law Firm announces that it is investigating the Board of Directors of Avanir Pharmaceuticals, Inc.

Stocks Gain as Construction Spending Expands, Global Stimulus Talk Heats Up

Stocks Gain as Construction Spending Expands, Global Stimulus Talk Heats Up

U.S. stocks book modest gains on Tuesday morning as domestic construction spending expands.

Avanir Fetches $3.5B From Japan's Otsuka for Reformulated Cough Syrup

Avanir Fetches $3.5B From Japan's Otsuka for Reformulated Cough Syrup

The Japanese drugmaker is trying to shore up its product pipeline ahead of April 2015 when patents on its best-selling schizophrenia drug Abilify expire.

Stock Futures Rise as Wall Street Recovers From Tech, Retail Selloff

Stock Futures Rise as Wall Street Recovers From Tech, Retail Selloff

U.S. stock futures edge higher on Tuesday after a selloff among tech and retail names left all benchmark indices in the red a day earlier.

AVANIR Pharmaceuticals (AVNR) Is Today's Pre-Market Mover With Heavy Volume Stock

AVANIR Pharmaceuticals (AVNR) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a pre-market mover with heavy volume candidate

Avanir Pharmaceuticals (AVNR) Stock Surges Today on $3.54 Billion Otsuka Deal

Avanir Pharmaceuticals (AVNR) Stock Surges Today on $3.54 Billion Otsuka Deal

Avanir Pharmaceuticals (AVNR) will be purchased by Otsuka Holdings Co. for about $3.54 billion, a deal that gives the Japanese company new treatments for neurological conditions,

December 2 Premarket Briefing: 10 Things You Should Know

December 2 Premarket Briefing: 10 Things You Should Know

U.S. stock futures rise slightly; Avanir to be bought by Japan's Otsuka Pharmaceutical; Cypress to buy Spansion; Ford and GM to report monthly sales.

Volume Plummeted Before the Holiday

Mediocre market internals continued the dull pace.

Two Small-Cap Biotechnology Gems

For speculative investors.

Low-Risk Trade Setups Hard to Find

But basing action in the last two weeks is helping.

Avanir Pharmaceuticals (AVNR) Stock Drops After FDA Provides New Drug Application Feedback

Avanir Pharmaceuticals (AVNR) Stock Drops After FDA Provides New Drug Application Feedback

Shares of Avanir Pharmaceuticals (AVNR) fell after the FDA provided preliminary written feedback to the biopharmaceutical company regarding its New Drug Application (NDA) for its migraine treatment drug AVP-825.

Will Avanir Pharmaceuticals (AVNR) Stock React Today to This Analyst Action?

Will Avanir Pharmaceuticals (AVNR) Stock React Today to This Analyst Action?

Deutsche Bank initiated coverage of Avanir Pharmaceuticals (AVNR) with a 'buy' rating and a price target of $17.

Perilous Reversal Stock: AVANIR Pharmaceuticals (AVNR)

Perilous Reversal Stock: AVANIR Pharmaceuticals (AVNR)

Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's Post-Market Leader Stock

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a post-market leader candidate

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's Post-Market Leader Stock

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a post-market leader candidate